Literature DB >> 11161226

Radiofrequency ablation of unresectable hepatic malignancies: lessons learned.

A J Bilchik1, T F Wood, D P Allegra.   

Abstract

Radiofrequency ablation (RFA) is increasingly used for the local destruction of unresectable hepatic malignancies. Relative contraindications include tumors in proximity to vital structures that may be injured by RFA and lesions whose size exceeds the ablation capabilities of the probe system employed. Given current technology, we believe that RFA should be cautiously utilized for lesions greater than 5 cm in diameter. Open (celiotomy) and laparoscopic approaches to RFA allow intraoperative ultrasonography, which may demonstrate occult hepatic disease. In addition, RFA performed via celiotomy can be accompanied by resection or cryosurgical ablation, and isolation of the liver from adjacent organs. Percutaneous RFA should be reserved for patients who cannot undergo general anesthesia, those with recurrent or progressive lesions, and those with smaller lesions sufficiently isolated from adjacent organs. Complications may be minimized when these approaches are selectively applied.

Entities:  

Mesh:

Year:  2001        PMID: 11161226     DOI: 10.1634/theoncologist.6-1-24

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  29 in total

1.  Radiofrequency ablation in the liver close to the bile ducts: can intraductal cooling offer protection?

Authors:  U Jersenius; D Arvidsson; J Lindholm; S Anttila; A Elvin
Journal:  Surg Endosc       Date:  2005-03-11       Impact factor: 4.584

Review 2.  Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.

Authors:  Stefaan Mulier; Yicheng Ni; Jacques Jamart; Theo Ruers; Guy Marchal; Luc Michel
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

3.  Prevention of biliary lesions that may occur during radiofrequency ablation of the liver: study on the pig.

Authors:  Frédéric Marchal; Dominique Elias; Philippe Rauch; Rasa Zarnegar; Agnès Leroux; Joseph Stines; Jean-Luc Verhaeghe; François Guillemin; Jean Pierre Carteaux; Jean Pierre Villemot
Journal:  Ann Surg       Date:  2006-01       Impact factor: 12.969

4.  Incorporation of preprocedural PET into CT-guided radiofrequency ablation of hepatic metastases: a nonrigid image registration validation study.

Authors:  Peng Lei; Omkar Dandekar; David Widlus; Raj Shekhar
Journal:  J Digit Imaging       Date:  2009-05-27       Impact factor: 4.056

Review 5.  Evolving management of colorectal cancer.

Authors:  Jochem van der Voort van Zijp; Harald J Hoekstra; Marc D Basson
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

6.  Radiofrequency-assisted liver resection.

Authors:  Mattia Stella; Andrea Percivale; Massimo Pasqualini; Alberto Profeti; Nicola Gandolfo; Giovanni Serafini; Riccardo Pellicci
Journal:  J Gastrointest Surg       Date:  2003 Sep-Oct       Impact factor: 3.452

7.  Risk of burn trauma during circumcision with radiofrequency scalpel: case report and review of literature.

Authors:  Ali Akbar Mohammadi; Seyed Morteza Seyed Jafari; Ahmad Abdollahi
Journal:  Int J Burns Trauma       Date:  2013-07-08

8.  Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients.

Authors:  Timothy M Pawlik; Francesco Izzo; Deborah S Cohen; Jeffery S Morris; Steven A Curley
Journal:  Ann Surg Oncol       Date:  2003-11       Impact factor: 5.344

Review 9.  Current treatment for liver metastases from colorectal cancer.

Authors:  Lian-Xin Liu; Wei-Hui Zhang; Hong-Chi Jiang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

10.  Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results.

Authors:  John Wong; Kit-Fai Lee; Simon Chun-Ho Yu; Paul Sing-Fun Lee; Yue-Sun Cheung; Ching-Ning Chong; Philip Ching-Tak Ip; Paul Bo-San Lai
Journal:  HPB (Oxford)       Date:  2012-11-28       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.